Navigation Links
Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain
Date:4/16/2008

reached for the primary endpoint in SP743, likely due to a strong placebo effect at the final visit.

Additionally, a meta-analysis of all Phase III, fixed-dose trials showed a significant mean reduction in pain score of -2.14 for the lacosamide group compared with -1.57 for placebo (p=0.0006). Results on the secondary outcome of pain reduction from baseline through the entire maintenance period were also statistically significant for all fixed-dose trials (p=<.001).

Pooled Safety Analysis

In these trials, the overall percentage of patients who discontinued treatment due to adverse events was similar between the placebo group and the lacosamide 200 and 400 mg/day groups (24.7 percent, 29.9 percent and 32.9 percent, respectively). The percentage was higher (55.4 percent) in the group receiving 600 mg/day of lacosamide.

Overall, treatment emergent adverse events (TEAEs) were reported by a similar percentage of patients in the placebo (72.9 percent) and in the pooled lacosamide groups (76.3 percent). The most frequently reported TEAEs in the pooled lacosamide group, which were greater than placebo, were dizziness (16.3 vs. 5.2 percent), nausea (10.3 vs. 6.2 percent), fatigue (6.7 vs. 4.1 percent) and tremor (6.5 vs. 1.0 percent). In addition, lacosamide had no effect on body weight in these trials.

About lacosamide

Lacosamide has a dual mode of action and is the first agent of its kind to be clinically studied for the treatment of diabetic neuropathic pain. It selectively enhances slow inactivation of sodium channels and interacts with the collapsin-response mediator protein-2 (CRMP-2). Lacosamide is also being investigated for its potential as adjunctive therapy to treat partial onset seizures in adults with epilepsy.

Lacosamide oral tablet has been filed with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) for the treatment of diabetic neuropathic pain. Applications for marketing au
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
6. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... 17 The Make-A-Wish Foundation announced today ... from the LATISSE ® ... Allergan, Inc. ,, Based on the tradition of ... come true, the campaign launched earlier this year ... Foundation by leveraging the excitement around the availability ...
(Date:12/16/2009)... Dec. 17 Cell Therapeutics, Inc. ... that on February 10, 2010 the U.S. ... Committee (ODAC) will review the New Drug ... of relapsed/refractory aggressive non-Hodgkin,s lymphoma (NHL). ODAC ... evaluates data concerning the efficacy and safety ...
(Date:12/16/2009)... , Dec. 16 MedSolutions ( ... management services, today commended two new studies highlighting ... scans and other diagnostic imaging tests. ,, ... proper diagnosis and treatment," said Gregg Allen, M.D., ... studies offer more compelling evidence that stricter quality ...
Breaking Medicine Technology:The Make-A-Wish Foundation(R) Receives $1 Million Donation from LATISSE(R) Wishes Campaign 2The Make-A-Wish Foundation(R) Receives $1 Million Donation from LATISSE(R) Wishes Campaign 3The Make-A-Wish Foundation(R) Receives $1 Million Donation from LATISSE(R) Wishes Campaign 4The Make-A-Wish Foundation(R) Receives $1 Million Donation from LATISSE(R) Wishes Campaign 5Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 2Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 3Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 4MedSolutions Applauds Renewed Focus on the Dangers of Radiation Exposure 2MedSolutions Applauds Renewed Focus on the Dangers of Radiation Exposure 3American Investors Highlight Successes in Eastern Germany 48753 1American Investors Highlight Successes in Eastern Germany 48753 2Healthcare Travel Congress 2009 3A Experts Worldwide Convene in Singapore For Regional Conference on Medical Tourism 48752 1Healthcare Travel Congress 2009 3A Experts Worldwide Convene in Singapore For Regional Conference on Medical Tourism 48752 2Healthcare Travel Congress 2009 3A Experts Worldwide Convene in Singapore For Regional Conference on Medical Tourism 48752 3Tasty Baking Company Supports the Fight Against Childhood Cancer Through Partnership with Alexs Lemonade Stand Foundation 48750 1Tasty Baking Company Supports the Fight Against Childhood Cancer Through Partnership with Alexs Lemonade Stand Foundation 48750 2Tasty Baking Company Supports the Fight Against Childhood Cancer Through Partnership with Alexs Lemonade Stand Foundation 48750 3
... BIRMINGHAM, Ala., April 03, 2007 /PRNewswire/ -- Southern,Research ... research in the areas of preclinical drug,discovery and ... delivering one oral presentation and 10 poster,presentations at ... Meeting, April 14-18 in Los Angeles, Calif. , ...
... Absorption of Fat and Protein during Clinical ... 04, 2007 /PRNewswire/ --,Eurand, a global specialty ... III clinical trials on its lead product,candidate, ... Pancreatic Insufficiency (EPI). The US Food and ...
Other Medicine Technology:Southern Research Institute to Present at the 2007 American,Association For Cancer Research Annual Meeting 2Southern Research Institute to Present at the 2007 American,Association For Cancer Research Annual Meeting 3Eurand Announces Positive Phase III Clinical Study Results 2Eurand Announces Positive Phase III Clinical Study Results 3Eurand Announces Positive Phase III Clinical Study Results 4Eurand Announces Positive Phase III Clinical Study Results 5
(Date:12/17/2009)... in Majority Leader,s Revisions to Senate Health Care ... Americans United for Life Action President, ... Senate Majority Leader Harry Reid as he considers ... to a bill - to the Senate health ... include "specific language that ensures your legislation comprehensively ...
(Date:12/17/2009)... clothing stores, gas stations -- and adding to obesity epidemic, ... you,re hungry while shopping for a new sofa, don,t despair: ... salty snacks, a new report finds. , In fact, the ... stores to hit most segments of the retail market, say ... the American Journal of Public Health . The ...
(Date:12/17/2009)... in the outbreak is a good time to get ... (HealthDay News) -- As the current wave of H1N1 ... Thursday urged that everyone get vaccinated in case another ... of the H1N1 flu vaccine have eased, it,s an ... Human Services Secretary Kathleen Sebelius said during a morning ...
(Date:12/17/2009)... Dec. 17 Reportlinker.com announces that ... in its catalogue: ,, http://www.reportlinker.com/p0169956/Top-Ten-Worlds-Leading-Animal-Health-Companies.html ... provide the animal health industry executives with ... critical to the development and implementation of ... major objectives include: ,, To ...
(Date:12/17/2009)... KONG, Dec. 17 /PRNewswire-Asia/ -- China,s leading high-tech,healthcare ... "the,Group"; Stock Code: 801) is pleased to announce ... Limited (FunTalk), formerly known as,Pypo China Holdings Limited, ... FTLK ) after a successful secondary offering. The ... morning (Eastern Time). , ...
Breaking Medicine News(10 mins):Health News:Pro-Life Leader Sends Urgent Letter to Senator Reid 2Health News:Wide Array of Stores Now Sell High-Calorie Snacks 2Health News:Swine Flu Wanes, But Future Uncertain 2Health News:Reportlinker Adds Top Ten World's Leading Animal Health Companies 2Health News:Reportlinker Adds Top Ten World's Leading Animal Health Companies 3Health News:Reportlinker Adds Top Ten World's Leading Animal Health Companies 4Health News:Golden Meditech's Associate Company Debuted on NASDAQ 2
... Amcat,s Contact Center Suite operates with Gryphon compliance ... resulting in increased productivity for call ... a leading provider of,intelligent customer interaction solutions, today ... Gryphon Networks, the worldwide leader in,On-Demand Contact Governance ...
... spell the end of pen-and-paper questionnaires/ , Here ... boring questionnaires may soon be obsolete! Well, at least ... must be monitored by doctors. Thanks to the RT3 ... the hassle of keeping a journal or completing activity ...
... Breast cancer survivors who took a weekly dose of ... those who did not take the drug, according to ... of Medicine presented this week at the 29th annual ... Research. Scientific sessions continue through Wednesday at the Hawaii ...
... 30 years of Healthcare Management Expertise, PHILADELPHIA, ... Network Management solutions, today announced the addition of ... California, to its board,of directors. "Jon,s deep ... country,s,largest HMOs is a tremendous asset to Portico ...
... In the face of an emerging liver cancer crisis in ... developed a test that could help millions. Due to widespread ... population is at high risk for hepatocellular carcinoma (HCC), a ... treated early. Researchers report on a new blood screening ...
... and Other Heart Health Advocates to Offer, Inspiration and Information on ... ... Impact, ENGLEWOOD CLIFFS, N.J., Sept. 18 Have you ever made ... the most heart-felt personal commitments can often fall by the,wayside. A new highly ...
Other Medicine News:Health News:Amcat Partners With Gryphon to Provide Comprehensive and Guaranteed Do Not Call (DNC) Compliance Solution for Outbound Contact Activities 2Health News:Amcat Partners With Gryphon to Provide Comprehensive and Guaranteed Do Not Call (DNC) Compliance Solution for Outbound Contact Activities 3Health News:Story tips for journalists 2Health News:Story tips for journalists 3Health News:Weekly dose of osteoporosis drug prevents bone loss after breast cancer treatment 2Health News:Jon R. Wampler Joins Portico Systems' Board of Directors 2Health News:Liver cancer marker could yield blood test for early detection 2Health News:Liver cancer marker could yield blood test for early detection 3Health News:Liver cancer marker could yield blood test for early detection 4Health News:Leeza Gibbons Leads New Coaching Program to Boost the Nation's Heart Health 2Health News:Leeza Gibbons Leads New Coaching Program to Boost the Nation's Heart Health 3Health News:Leeza Gibbons Leads New Coaching Program to Boost the Nation's Heart Health 4
... you need quick, accurate, convenient, and cost-effective ... VITROS DT60 II Chemistry System. This easy-to-use ... back-up laboratory testing requirements. And it helps ... better patient outcomes, reduced overall costs, and ...
... provides power and efficiency to ... volume testing facilities. With fast ... results per hour, the Vitros ... the full complement of Vitros ...
... Abbott entered the Therapeutic Drug Monitoring ... the TDx. Still in use today, this ... Polarization Immunoassay) to measure serum drug concentration ... the treatment of different diseases, often exhibit ...
AxSYM Plus provides cutting-edge ergonomics and smart new features that mean increased ease-of-use and enhanced reliability. Also, advanced software means less operator intervention and high-integrit...
Medicine Products: